- $99.29m
- -$120.71m
- $19.09m
U.S. STOCKS ON THE MOVE-Biocept, Molson Coors, DCP Midstream
U.S. STOCKS ON THE MOVE-Geron, Southwest Airlines, Borr Drilling
Refinitiv Newscasts - U.S. Morning Call: Stocks flat in premarket ahead of expected strong jobs data
Graphite Bio tumbles after halting trial for blood disease therapy
Graphite Bio pauses early-stage blood disease therapy trial
Brief: Graphite Bio Announces Voluntary Pause Of Phase 1/2 Cedar Study Of Nulabeglogene Autogedtemcel (Nula-Cel) For Sickle Cell Disease
Brief: Graphite Bio Reports Third Quarter 2022 Financial Results
Brief: Graphite Bio Reports Recent Business Progress And Second Quarter 2022 Financial Results
Brief: Graphite Bio Doses First Patient With Investigational Gene Editing Therapy Gph101 For Sickle Cell Disease
Brief: Graphite Bio Doses First Patient With Investigational Gene Editing Therapy Gph101 For Sickle Cell Disease
Brief: Graphite Bio Inc Files For Mixed Shelf Of Up To $300 Mln
Several biotechs trading below cash position - Evercore ISI
U.S. RESEARCH ROUNDUP-First Solar, Henry Schein, Petiq
Brief: Graphite Bio Reports Q1 2022 Financial Results
Brief: Graphite Bio Announces U.S. FDA Fast Track Designation Granted To Gph101 For The Treatment Of Sickle Cell Disease
U.S. RESEARCH ROUNDUP-Macerich, Progressive, Twitter
U.S. RESEARCH ROUNDUP- Cepton, Helios Technologies, Marinus Pharmaceuticals
Brief: Graphite Bio Reports Q4 Loss Per Share $0.35
Brief: Graphite Bio Appoints Alethia Young As Chief Financial Officer